文献速递乳房整形与再造

脱细胞真皮基质在即刻扩张器/假体乳房再造中的多中心风险评估

Acellular Dermal Matrix in Immediate Expander/Implant Breast Reconstruction: A Multicenter Assessment of Risks and Benefits.
PubMed 文献 · Plast Reconstr Surg · 2017-01-01

基于乳房切除再造结局联盟的前瞻性队列,纳入10中心58位术者2012至2015年间1297例即刻组织扩张器再造患者,其中655例(50.5%)使用脱细胞真皮基质。控制人口学与临床协变量后,2年总体并发症、主要并发症、伤口感染、再造失败及患者报告结局均无显著差异。

要点

  • 使用与未使用脱细胞真皮基质的患者在2年并发症与再造失败上无显著差异。
  • 两组扩张器/假体置换时间及BREAST-Q各维度与疼痛评分均无显著差异。
  • 证据等级为治疗性II级,提示需进一步制定选择性使用该材料的标准。

核心结论

  • 多中心前瞻性分析未发现脱细胞真皮基质对即刻扩张器/假体乳房再造的并发症、置换时间或患者报告结局有显著影响。

研究设计与样本

  • 乳房切除再造结局联盟的前瞻性队列研究,覆盖10个中心、58位术者,2012至2015年纳入1297例即刻组织扩张器再造患者,655例(50.5%)使用脱细胞真皮基质,642例(49.5%)未使用;采用双变量分析与混合效应回归模型,证据等级为治疗性II级。

主要发现

  • 控制协变量后,2年总体并发症OR 1.21(p=0.263)、主要并发症OR 1.43(p=0.052)、伤口感染OR 1.49(p=0.118)、再造失败OR 1.55(p=0.089)均无显著差异。
  • 两组扩张器/假体置换时间无显著差异(p=0.78)。
  • 乳房满意度、心理社会幸福感、性幸福感、身体健康与术后疼痛等患者报告结局评分均无显著差异。

临床怎么用

  • 现有证据不支持仅以降低并发症或改善患者报告结局为由常规使用脱细胞真皮基质,宜结合个体情况选择性应用。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acellular dermal matrix has gained widespread acceptance in immediate expander/implant reconstruction because of perceived benefits, including improved expansion dynamics and superior aesthetic results. Although previous investigators have evaluated its risks, few studies have assessed the impact of acellular dermal matrix on other outcomes, including patient-reported measures. METHODS: The Mastectomy Reconstruction Outcomes Consortium Study used a prospective cohort design to evaluate patients undergoing postmastectomy reconstruction from 10 centers and 58 participating surgeons between 2012 and 2015. The analysis focused on women undergoing immediate tissue expander reconstruction following mastectomies for cancer treatment or prophylaxis. Medical records and patient-reported outcome data, using the BREAST-Q and Numeric Pain Rating Scale instruments, were reviewed. Bivariate analyses and mixed-effects regression models were applied. RESULTS: A total of 1297 patients were evaluated, including 655 (50.5 percent) with acellular dermal matrix and 642 (49.5 percent) without acellular dermal matrix. Controlling for demographic and clinical covariates, no significant differences were seen between acellular dermal matrix and non-acellular dermal matrix cohorts in overall complications (OR, 1.21; p = 0.263), major complications (OR, 1.43; p = 0.052), wound infections (OR, 1.49; p = 0.118), or reconstructive failures (OR, 1.55; p = 0.089) at 2 years after reconstruction. There were also no significant differences between the cohorts in the time to expander/implant exchange (p = 0.78). No significant differences were observed in patient-reported outcome scores, including satisfaction with breasts, psychosocial well-being, sexual well-being, physical well-being, and postoperative pain. CONCLUSIONS: In this multicenter, prospective analysis, the authors found no significant acellular dermal matrix effects on complications, time to exchange, or patient-reported outcome in immediate expander/implant breast reconstruction. Further studies are needed to develop criteria for more selective use of acellular dermal matrix in these patients. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Sorkin M, Qi J, Kim HM, et al. Acellular Dermal Matrix in Immediate Expander/Implant Breast Reconstruction: A Multicenter Assessment of Risks and Benefits. Plast Reconstr Surg. 2017. PMID: 28806288. doi:10.1097/PRS.0000000000003842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。